Kepler Capital Markets set a €105.00 ($122.09) price target on Merck KGaA (FRA:MRK) in a research report sent to investors on Friday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities analysts have also commented on MRK. Goldman Sachs Group set a €92.00 ($106.98) target price on Merck KGaA and gave the company a neutral rating in a report on Monday, July 9th. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a buy rating in a report on Monday, July 16th. Barclays set a €70.00 ($81.40) target price on Merck KGaA and gave the company a sell rating in a report on Monday, July 16th. DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a report on Monday, July 23rd. Finally, JPMorgan Chase & Co. set a €90.00 ($104.65) target price on Merck KGaA and gave the company a neutral rating in a report on Wednesday, July 25th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has an average rating of Hold and an average price target of €99.38 ($115.56).
Shares of FRA:MRK traded down €0.40 ($0.47) during trading on Friday, hitting €94.68 ($110.09). 572,134 shares of the company traded hands. Merck KGaA has a one year low of €76.60 ($89.07) and a one year high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Read More: How is an ETF different from a mutual fund?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.